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ABSTRACT 
 
Objective: We evaluated the effectiveness of short-term cash and food assistance to improve 
adherence to antiretroviral therapy (ART) and retention in care among people living with HIV 
(PLHIV) in Tanzania. 
Methods: At three clinics, 805 participants were randomized to three groups in a 3:3:1 ratio, 
stratified by site: nutrition assessment and counseling (NAC) plus cash transfers (~$11/month, 
n=347), NAC plus food baskets (n=345), and NAC-only (comparison group, n=113, 
clinicaltrials.gov NCT01957917). Eligible PLHIV were: ≥18 years, initiated ART ≤90 days prior, 
and food insecure. Cash or food was provided for ≤6 consecutive months, conditional on visit 
attendance. The primary outcome was medication possession ratio (MPR) ≥95% at 6 months. 
Secondary outcomes were appointment attendance and loss to follow-up (LTFU) at 6 and 12 
months. 
Results: The primary intent-to-treat analysis included 800 participants. Achievement of 
MPR≥95% at 6 months was higher in the NAC+cash group compared to NAC-only (85.0% vs. 
63.4%), a 21.6 percentage point difference (95% confidence interval (CI): 9.8, 33.4, p<0.01). 
MPR≥95% was also significantly higher in the NAC+food group versus NAC-only 
(difference=15.8, 95% CI: 3.8, 27.9, p<0.01). When directly compared, MPR≥95% was similar in 
the NAC+cash and NAC+food groups (difference=5.7, 95% CI: -1.2, 12.7, p=0.15). Compared 
to NAC-only, appointment attendance and LTFU were significantly higher in both the NAC+cash 
and NAC+food groups at 6 months. At 12 months, the effect of NAC+cash, but not NAC+food, 
on MPR≥95% and retention was sustained. 
Conclusions: Short-term conditional cash and food assistance improves ART possession and 
appointment attendance and reduces LTFU among food-insecure ART initiates in Tanzania.  
 
KEYWORDS: Food security, HIV infection, adherence, retention, impact evaluation, cash 
transfers, food assistance 
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INTRODUCTION 
Although early initiation of antiretroviral therapy (ART) among people living with HIV/AIDS 
(PLHIV) has significant clinical benefits and can virtually eliminate onward HIV transmission,[1, 2] 
these benefits hinge on high levels of ART adherence. Most treatment regimens require more 
than 80-95% ART adherence to maximize the probability of viral suppression,[3-6] the ultimate 
goal of HIV treatment.[2, 7] However, in sub-Saharan Africa (SSA) nearly 25% of PLHIV on 
treatment have sub-optimal adherence and overall, only 29% of PLHIV are virally suppressed.[8, 
9] Thus, achievement of UNAIDS’ ambitious ’90-90-90’ strategy, which requires that by 2020, 
90% of PLHIV who receive ART will have viral suppression, necessitates new and effective 
strategies to bolster ART adherence and retention in care. 
In SSA, poor ART adherence and disengagement from care are often the detrimental 
consequences food insecurity.[10, 11] People are considered food secure when they have 
adequate physical, social, and economic access to sufficient, safe and nutritious food that 
meets their dietary needs and food preferences for an active and healthy life.[12] Food insecurity 
hinders HIV treatment by increasing the likelihood of hunger or exacerbated side effects 
associated with ART, by increasing anxiety and stress, and by forcing PLHIV to make difficult 
choices between food and other goods and services, including HIV care.[11, 13] Thus, there is 
growing interest in the potential for food and economic programs to mitigate food insecurity, 
improve the health of PLHIV, and enhance the effectiveness of HIV treatment programs. 
Interventions in the form of food baskets or cash transfers have the potential to achieve 
these goals. For example, four[14-17] of five studies of programs that provided food baskets or 
nutritional supplementation to PLHIV found positive effects on at least one measure of treatment 
adherence.[14-18] Likewise, cash incentives can also improve ART adherence and/or viral 
suppression compared to the standard of care.[19-22] Cash transfers are particularly attractive 
because they give beneficiaries freedom of choice, they may be cheaper to distribute and easier 
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to monitor, and because their increasing adoption by anti-poverty programs across SSA may 
signal political and logistical readiness for cash transfer programs delivered at scale.[23, 24]  
Despite these promising results, there are limited rigorous data from low- and middle-
income countries about whether cash and food assistance programs for PLHIV are effective for 
improving adherence or retention.[25] To address this gap, we compared the standard of care to 
two models of short-term support for food insecure PLHIV in Tanzania who recently initiated 
treatment: cash transfers and food assistance. All three groups received nutrition assessment 
and counseling (NAC). We focused on ART initiates for several reasons including the increased 
risk of mortality associated with a low BMI in the first years of treatment,[26-28] the potential to 
accelerate habit formation,[29] and the goal to bolster household labor supply and productivity 
during the vulnerable time of treatment initiation.[30] The study’s objective was to examine the 
comparative effectiveness of cash and food assistance on ART adherence and retention in care 
at 6 and 12 months. 
 
METHODS 
Study Design 
We conducted a 3-arm randomized trial to examine the comparative effectiveness of short-term 
cash and food assistance added to the standard of care HIV services that included NAC. We 
recruited participants from three facilities (two hospitals and one peri-urban clinic) in Shinyanga, 
a resource-limited region in Tanzania where HIV prevalence is 7.4%.[31] Participants were 
prospectively followed for 12 months. All facilities were implementing the President’s 
Emergency Plan for AIDS Relief Nutrition Assessment, Counseling, and Support (NACS) 
program.[32] Study procedures have been previously described,[33] the trial was pre-registered 
(clinicaltrials.org, NCT01957917), and here we report the study according to the CONSORT 
2010 guidelines.[33, 34] The Tanzanian National Institute for Medical Research and the Committee 
for Protection of Human Subjects at the University of California, Berkeley approved this study. 
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Participants 
Eligible PLHIV were: 1) ≥18 years of age; 2) newly initiated on ART ≤90 days prior; 3) food 
insecure, as measured with the Household Hunger Scale (HHS, score ≥2)[35]; and 4) willing and 
able to provide written informed consent. During the first two months of the study, PLHIV who 
were moderately (body mass index (BMI) 16-18.5 kg/m2) or severely malnourished (BMI<16 
kg/m2) were excluded due to their need to receive special nutritional and clinical support for 
recovery. However, given the frequency of moderate malnutrition among ART initiates and the 
lack of any special nutritional or clinical services for this group at study sites, we determined that 
moderately malnourished patients would be eligible for inclusion.  
 
Randomization and Masking 
Participants were individually randomized to one of three study arms: NAC alone (standard-of-
care comparison condition), NAC plus cash transfers, and NAC plus food assistance in a 1:3:3 
ratio, stratified by site, using random permuted block sizes of 7, 14, and 21. Randomization 
procedures were conducted at the University of California, Berkeley using Stata 12 (College 
Station, Texas); procedures and group assignments were inaccessible to the local research 
team. Random assignments were listed in opaque sealed envelopes that were sequentially 
numbered. After written informed consent was obtained, research staff selected the next 
envelope in numeric order and broke the seal to reveal the group assignment. Participants and 
investigators were not masked.  
 
 
Procedures 
Participants in the comparison arm received the standard HIV primary care services available in 
Tanzania, including NAC. Participants in the cash and food arms received the standard of care 
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services plus the opportunity to receive a monthly cash transfer or food basket for up to 6 
consecutive months, conditional on attending scheduled visits with the HIV care provider 
(typically monthly). Visits meeting the condition for assistance were ≥26 days apart and 
occurred within a 4-day window (+/- 4 days) from the scheduled visit. Food baskets and cash 
transfers were distributed on the same two days per month. 
The cash transfer was 22,500 Tanzanian Shillings (approximately $11 USD, $66 
maximum during the intervention period) and was equivalently valued to the food basket. This 
value was selected to prevent undue coercion and be comparable to the Tanzania Social Action 
Fund (TASAF), a government-run anti-poverty program which provides $6-18 monthly to 
qualified households.[36] Cash, including transaction fees, was transferred via mobile money 
services (i.e., M-PESA). If participants did not have access to a mobile phone, cash was 
provided directly.  
The food basket was valued at approximately $11 and included whole maize meal (12 
kg), groundnuts (3kg), and beans (3kg), and was determined with the input of experts in 
academic, government, and donor organizations. The basket was intended to be applicable to 
other settings, not cost-prohibitive, be similar to prior programs, and use locally available food. 
Because the goal was to supplement, but not replace, the household’s food supply, the food 
basket was significantly smaller than food baskets evaluated in other studies to improve ART 
adherence.[14-18] 
At baseline, 6, and 12 months, research assistants conducted in-person interviews in 
Kiswahili with participants about individual and household characteristics, food security, self-
reported ART adherence, health service utilization, and preference for food or cash if given the 
choice. Visit attendance, CD4 count, pharmacy dispensing, and other clinical and prognostic 
markers were abstracted from medical and pharmacy records at baseline, 6 and 12 months. 
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Outcomes 
The primary outcome was ART adherence at 6 months, measured as the proportion of patients 
with medication possession ratio ≥95% during the 0-6 month interval (MPR≥95%). MPR is the 
proportion of days in a specified interval that an individual is in possession of ≥1 ART dose.[37] 
MPR is computed from pharmacy dispensing records and achievement of ≥95% MPR is 
associated with short-term virologic outcomes.[37, 38] When patients transferred, opted-out of 
future study participation, or died, we truncated the 0-6 month interval to the last visit date. 
We included several secondary outcomes. We assessed MPR≥95% at 12 months. In 
addition, because adherence thresholds between 80%-95% may be correlated with viral 
suppression,[4, 5, 37] we assessed secondary outcomes of MPR≥80% (binary) and MPR 
(continuous scale) for the 0-6 and 0-12 month intervals. We also assessed retention in care at 6 
and 12 months in two ways. We first determined “appointment attendance,” the proportion of 
scheduled visits completed during the 0-6 and 0-12 month observation periods.[39] We also 
determined loss to follow-up (LTFU), defined as ≥90 days since the last scheduled visit.[40, 41] 
Patients who transferred clinics or opted-out of future participation were excluded from 
denominator of the LTFU indicator but those who died were retained in the denominator, similar 
to PEPFAR indicators.[42]  
 
Statistical Analysis 
The target sample size was determined using a non-inferiority design to compare the 
effectiveness of cash transfers versus food assistance on MPR≥95% at 6 months.[33] We 
estimated that 75% of participants in the food group would have an MPR≥95%,[9, 43, 44] and we 
set a non-inferiority limit (∆) of 10 percentage points for the cash group to be determined non-
inferior. The non-inferiority margin was determined as the largest loss of effect (inferiority) that 
would be clinically acceptable when comparing cash transfers to food baskets.[45] With these 
assumptions, power=80% and alpha=0.025 for a one-sided hypothesis test, 339 participants 
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were required in each of the cash and food transfer arms, assuming 15% loss to follow-up. A 
secondary objective was to determine whether any assistance (NAC plus food or cash transfers, 
combined) was superior to NAC alone. For this objective, we required a comparison group of 
110 participants to detect at least a 15 percentage point increase in MPR≥95%, assuming 60% 
of participants achieve MPR ≥95% in the NAC-only comparison arm, 15% loss to follow-up, and 
alpha=0.05. This was determined to be a clinically meaningful minimum detectable effect size 
and feasible to measure given study constraints. 
We first assessed baseline differences in participant characteristics between arms using 
chi-square and Kruskal-Wallis tests. We then conducted an intent-to-treat (ITT) analysis by 
constructing a logistic regression model and expressing differences in the primary outcome 
between arms as risk differences with 95% confidence intervals (CI) using the margins 
command in STATA 14 (College Station, Texas). Following our pre-specified analysis plan,[33] 
we first assessed whether NAC plus cash transfers was non-inferior to NAC plus food 
assistance, defined as the lower 95% CI of the between-group difference in MPR≥95% lying 
above a threshold of −10% after applying Bonferroni’s correction for multiple comparisons.[46, 47] 
Because non-inferiority was evident, we conducted pairwise comparisons of the three groups 
using a Wald test with alpha = 0.05 and Bonferroni’s correction, using the pwcompare command 
in STATA. 
We conducted several secondary analyses. These included an analysis of the primary 
outcome adjusted for site and factors imbalanced at baseline, and an analysis of results by 
quarter. We examined the effect of the intervention on secondary outcomes, including 
MPR≥80% and MPR at 6 and 12 months, MPR≥95% at 12 months, and appointment 
attendance and loss to follow-up at 6 and 12 months, by generating risk differences and 95% 
CIs from logistic and OLS regression models as appropriate.  In addition, the effect of the 
interventions on the time to LTFU (the time between study enrollment and the last scheduled 
visit) was examined with a Kaplan-Meier plot; equality of survival functions was tested using the 
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log-rank test. The effect of the interventions on the time to LTFU was examined using a Cox 
proportional hazards model with an interaction between study arm and categorical time at 3 and 
6 months to relax the proportional hazards assumption. We present hazard ratios (HR) for each 
time interval and 95% CIs. 
 
RESULTS 
Recruitment and enrollment was conducted from December 2, 2013 until July 22, 2015. Follow-
up continued until August 17, 2016 (Figure 1). We recruited and randomized 805 participants 
(805 of 819 (98%) eligible patients agreed to participate). Five patients transferred, died, opted 
out before their next scheduled visit (i.e., no follow-up time), or had no medical records and 
were subsequently excluded, leaving 800 participants for the primary ITT analysis at 6 months. 
At enrollment, 63% of participants were female, the median age was 35 years, median 
CD4 count was 200 cells/mm3, and median body mass index was 21.0 kg/m2 (Table 1). 
Participant characteristics were balanced between groups with the exception of occupation, 
language, and WHO clinical stage. During the study period, we distributed 1,794 cash transfers 
and 1,467 food baskets with no adverse events. When asked about their preferences at 6 
months, most intervention participants preferred cash (65%), regardless of study arm. 
  Per our pre-specified analysis plan, at 6 months NAC+cash was non-inferior to 
NAC+food on the primary outcome of MPR≥95% (unadjusted difference=5.7, 95% CI: -1.2, 
12.7, Table 2). In addition, participants in the pooled group of NAC+cash and NAC+food 
achieved significantly better MPR≥95% compared to the NAC-only group at 6 months 
(unadjusted difference=18.7, 95% CI: 9.4, 28.1, p<0.01). When disaggregated, the NAC+cash 
group attained significantly higher adherence than the comparison group on all indicators at 6 
months, including MPR≥95%, MPR≥80%, and MPR in both the ITT and adjusted analyses. In 
particular, MPR≥95% was achieved by 85.0% of patients in the NAC+cash group compared to 
63.4% in the NAC-only group, a 21.6 percentage point difference in unadjusted analyses (95% 
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confidence interval (CI): 9.8, 33.4, p<0.01). In the NAC+food group, MPR≥95% and MPR were 
significantly greater (79.2%, 92.9%, respectively) than the comparison group (63.4%, 85.4%, 
respectively) at 6 months in both the ITT and adjusted analysis, although the effect on 
MPR≥80% was only significant in adjusted analyses (87.7% vs. 79.5%, adjusted difference=9.4, 
95% CI: 0.1, 18.8, p<0.05). When directly compared, NAC+cash was statistically similar to 
NAC+food at improving 6-month MPR≥95% and MPR, although in both ITT and adjusted 
analyses MPR≥80% was significantly higher in the NAC+cash group (adjusted difference=5.8, 
95% CI: 0.8, 10.8, p=0.02).  
At 12 months, MPR≥95% was significantly greater among those in the NAC+cash group 
than the NAC-only group (74.9% vs. 55.4%, adjusted difference=20.3, 95% CI: 8.4, 32.2, 
p<0.01, Table 2). Furthermore, compared to the NAC-only group, MPR remained significantly 
higher in the NAC+cash group (93.0% vs. 83.3%, p<0.01) and in the NAC+food group (89.5% 
vs. 83.3%, p<0.01) in both ITT and adjusted analyses. Neither intervention significantly 
improved MPR≥80% at 12 months. When directly compared, NAC+cash was significantly more 
effective than NAC+food at improving both 12 month MPR≥95% (adjusted difference=10.8, 95% 
CI: 3.0, 18.6, p<0.01) and MPR (adjusted difference=3.7, 95% CI: 0.5, 7.0, p<0.05). When 
observed in 3-month intervals, MPR≥95% was higher in the cash and food groups only during 
the initial 3 months of the intervention period (Figure 2).  
Compared to the NAC-only group, significantly higher appointment attendance at 6 
months was observed among those randomized to NAC+cash or NAC+food (Table 2): 
NAC+cash was associated with an adjusted 13.9 percentage point increase in appointment 
attendance at 6 months (95% CI: 9.5, 18.3, p<0.01) and NAC+food was associated with an 
adjusted 12.2 percentage point increase in appointment attendance (95% CI: 7.8, 16.6, p<0.01). 
At 12 months, appointment attendance remained significantly higher in the NAC+cash and 
NAC+food groups compared to the NAC-only group. There were no differences in appointment 
attendance between NAC+cash and NAC+food at 6 or 12 months. 
 11 
LTFU was significantly less likely in the two intervention groups at 6 months, with 10.9%, 
0.9%, and 1.5% of participants LTFU in the NAC-only, NAC+cash, and NAC+food groups, 
respectively (Table 2). LTFU was not significantly different between the two intervention groups 
at 6 or 12 months. In the time to event analysis of LTFU, the effect of NAC+cash and NAC+food 
on preventing LTFU was concentrated in the first three months of the program (Figure 3, log 
rank test<0.01), but the proportion retained remained higher in both groups after the 
interventions had ended at 6 months. Both the NAC+cash (adjusted HR=0.07, 95% CI: 0.02, 
0.24, p<0.01) and NAC+food groups (HRa=0.12, 95% CI: 0.04, 0.35, p<0.01) were associated 
with a significantly reduced hazard of LTFU during the first 0-3 months of follow-up, but not 
during the 3-6 or 6-9 month intervals (Table 3).  
 
DISCUSSION 
This study evaluated whether short-term cash or food assistance improves ART adherence and 
retention in care among food insecure HIV treatment initiates in Shinyanga, Tanzania. We found 
that at 6 months, both cash and food assistance increased medication possession and 
appointment attendance and reduced LTFU compared to the standard of care. At 12 months, 6 
months after the intervention period was complete, cash remained significantly associated with 
better adherence and retention in care. When directly compared, there were few differences 
between cash and food assistance, although cash was associated with significantly greater 
MPR≥80% at 6 months and MPR and MPR≥95% at 12 months. Taken together, these data 
suggest that short-term cash and food assistance are both valuable tools to maximize the 
effectiveness of ART programs for food insecure PLHIV when provided at treatment initiation. 
This study makes three key scientific contributions. First, although some, but not all, 
quasi-experimental studies have demonstrated that food or cash assistance may improve 
adherence to HIV treatment and/or care,[14-16, 18, 21, 25, 48, 49] this study is the first to directly 
compare each intervention against a comparison group using a randomized design. At the same 
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time, there are multiple evaluations in the economic development literature describing the 
relative merits of cash versus food assistance. In these studies, although both food and cash 
transfers increase food expenditure and food consumption, food transfers result in larger 
increases in caloric intake, they may be preferred by beneficiaries, and they may be more 
appropriate when food markets are functioning poorly.[24, 50, 51] In contrast, cash transfers allow 
freedom of choice, are cheaper to implement, and may be more “efficient” (according to 
microeconomic theory) than food transfers.[24, 50, 51] Until now, there were no equivalent data on 
the comparative effectiveness of different types of support among HIV-infected populations. The 
data from this study suggest that, at 6 months, the two strategies were statistically similar at 
improving most measures of adherence and retention among PLHIV versus the standard of 
care. At 12 months, cash was superior to food on two of the three adherence outcomes.  
A second contribution is that this study is the first, to our knowledge, to evaluate the 
effectiveness of conditional cash transfers (versus standard of care/no incentive) for improving 
ART adherence in SSA. Cash transfers have been shown to improve ART adherence, viral 
suppression, and/or retention in multiple studies in high-income countries.[19-22] Our findings 
suggest that cash transfer programs for PLHIV are acceptable, feasible, and effective in SSA. 
Furthermore, in addition to the few outcomes where cash was statistically superior to food, the 
ease of distribution through mobile money providers, lower distribution cost, and participant 
preference for cash suggests that short-term cash transfers may be a more promising 
intervention to consider for scale-up in many settings, an assertion suggested in other 
studies.[24, 50] Furthermore, it may be justified to consider expanding government-run cash 
transfer programs to HIV-affected households.[23, 36, 52, 53]  
 A third contribution of the study is the potential durability of the interventions’ effects on 
retention in care. Our analysis by quarterly interval indicates that the effect of cash and food 
transfers on LTFU is concentrated in the first three months after enrollment, which was by 
definition 0-90 days from the date of treatment initiation. However, after 12 months of follow-up, 
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retention in care remained approximately 8-12 percentage points higher in the cash and food 
groups versus the comparison group (a statistically significant difference among NAC+cash 
recipients). Thus, although the effect of cash transfers on retention are observed immediately 
after program initiation, they are sustained at 12 months. This finding is somewhat unexpected 
because prior incentive programs in health generally,[54] and HIV treatment adherence 
specifically,[19, 21] typically find that behavior returns to baseline levels after incentives are 
removed. These data suggest that in some contexts, short-term incentives may incite longer-
term benefits on retention, even after the incentives are withdrawn.  
This study has several limitations. We did not measure viral suppression; however, MPR 
is closely correlated with short-term viral load.[37, 38] In addition, there is the potential for poor 
data quality and missing data in paper-based facility registers; however, missing data was not 
differential by study arm and it would likely result in underestimates of ART adherence and 
retention. Lastly, our study was not powered to detect small differences between the two 
interventions. This study also has significant strengths, including the randomized design, 
inclusion of a standard of care comparison group, the focus on ART initiates, and participant 
follow-up after the incentive period. Furthermore, the study focused on food insecure PLHIV 
who were at risk of malnutrition in order to mitigate the effects of food insecurity before the 
development of undernutrition.[26-28]  
These findings demonstrate that short-term cash and food assistance for food insecure 
PLHIV initiating treatment improved ART adherence and retention in care during the incentive 
period. The early effects on adherence and retention were sustained in the cash group after the 
intervention was complete. Although the two interventions were statistically similar on some 
outcomes, the magnitude of cash transfers’ effects along with their simpler distribution warrants 
serious consideration of cash transfers along with other proven interventions as part of a 
comprehensive package of support at the time of treatment initiation. A larger-scale impact 
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evaluation to determine the effectiveness of short-term support on viral load, cost-effectiveness, 
and issues related to the potential for scale and sustainability is warranted. 
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FIGURE 1. Study profile.  
 
 
 
 
*4 screened patients were excluded for an unknown reason (e.g., missing screening data) 
921 patients assessed  
       for eligibility 
116 ineligible 
       102 did not meet inclusion criteria 
                2 started ART >90 days prior 
                1 aged <18 years 
              95 food secure 
                4 unknown reasons* 
          14 did not give informed consent 
113 assigned to NAC only,       
       comparison condition 
347 assigned to NAC plus  
       cash assistance 
112 included in intention-to-treat 
analysis on primary outcomes 
342 included in intention-to-treat 
analysis on primary outcomes 
1 excluded from analysis 
   1 died before first scheduled visit 
1 excluded from analysis 
   1 transferred to another clinic  
      before first scheduled visit      
3 excluded from analysis 
   1 opted out at first follow-up visit 
   1 transferred to another clinic  
       before first scheduled visit               
   1 missing all medical records 
805 randomized 
345 assigned to NAC plus  
       food assistance 
32 lost to study 
     23 before 6 months 
          16 lost to follow-up 
            3 transferred to another clinic 
            2 died 
            2 opted out 
       9 between 6 and 12 months 
            3 lost to follow-up 
            2 transferred to another clinic 
            1 died 
            3 opted out 
346 included in intention-to-treat 
analysis on primary outcomes 
88 lost to study 
     25 before 6 months 
            9 lost to follow-up 
          11 transferred to another clinic 
            4 died 
            1 opted out 
     63 between 6 and 12 months 
          18 lost to follow-up 
          35 transferred to another clinic 
            7 died 
            3 opted out 
82 lost to study 
     50 before 6 months 
          18 lost to follow-up 
          22 transferred to another clinic 
            3 died 
            7 opted out 
     32 between 6 and 12 months 
          17 lost to follow-up 
          13 transferred to another clinic 
            1 died 
            1 opted out 
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TABLE 1. Baseline sociodemographic and clinical characteristics of the intention-to-treat 
population.a 
  
  
  Study Group 
Overall (n=800) 
NAC only 
(n=112) 
NAC + Cash 
(n=346) 
NAC + Food 
(n=342) 
Sociodemographic Characteristics       
Age (years) 35 (29–43) 33 (28–40) 35 (30–42) 35 (29–44) 
Sex         
Male 291 (36%) 39 (35%) 128 (37%) 124 (36%) 
Female 509 (64%) 73 (65%) 218 (63%) 218 (64%) 
Language         
Swahili 489 (61%) 80 (71%) 205 (59%) 204 (60%) 
Sukuma/other 311 (39%) 32 (29%) 141 (41%) 138 (40%) 
Education (highest)         
Some pre-/primary school 121 (15%) 16 (14%) 57 (16%) 48 (14%) 
Primary school 437 (55%) 61 (54%) 191 (55%) 185 (54%) 
Secondary school or more 48 (6%) 12 (11%) 14 (4%) 22 (6%) 
No formal education 194 (24%) 23 (21%) 84 (24%) 87 (25%) 
Married/partnership 345 (43%) 49 (44%) 150 (43%) 146 (43%) 
Occupation         
Farmer 405 (51%) 47 (42%) 192 (55%) 166 (49%) 
Business 105 (13%) 25 (22%) 36 (10%) 44 (13%) 
Other 181 (23%) 27 (24%) 73 (21%) 81 (24%) 
Unemployed 109 (14%) 13 (12%) 45 (13%) 51 (15%) 
Currently  working 462 (58%) 72 (64%) 199 (58%) 191 (56%) 
Head of household 489 (61%) 68 (61%) 207 (60%) 214 (63%) 
Household size 3 (2–5) 3 (2–5) 3 (2–5) 3 (2–5) 
Severe household hungerb  328 (41%) 41 (37%) 141 (41%) 146 (43%) 
Travel time to clinic (minutes) 30 (20–60) 30 (20–60) 30 (20–60) 30 (20–60) 
Asset index         
1 200 (25%) 23 (21%) 87 (25%) 90 (26%) 
2 200 (25%) 28 (25%) 90 (26%) 82 (24%) 
3 200 (25%) 29 (26%) 92 (27%) 79 (23%) 
4 200 (25%) 32 (29%) 77 (22%) 91 (27%) 
          
Clinical Characteristics       
Body-mass index (kg/m2) 21.0 (19.1–23.0) 21.1 (19.8–23.3) 20.7 (19.1–22.5) 21.2 (19.1–23.4) 
Weight (kg) 56 (50–61) 58 (50–64) 55 (50-60) 56 (50–62) 
Days since ART started 14 (12–44) 14 (0–44) 14 (12–44) 14 (14–44) 
CD4 cell count (cells per μL) 200 (101–299) 188 (97–319) 192 (92–296) 214 (105–297) 
WHO clinical stage         
Stage 1 113 (14%) 14 (13%) 40 (12%) 59 (17%) 
Stage 2 230 (29%) 41 (37%) 88 (26%) 101 (30%) 
Stage 3 409 (51%) 46 (41%) 195 (57%) 168 (49%) 
Stage 4 44 (6%) 10 (9%) 20 (6%) 14 (4%) 
Pregnant 23 (3%) 1 (1%) 12 (3%) 10 (3%) 
Data are median (IQR) or n (%). NAC=nutrition assessment and counseling.      
a. Number of patients missing data for included variables: CD4 cell count: n=163, Body-mass index: n=28. All other 
variables have fewer than 10 values missing (<2%).  
b. According to the Household Hunger Scale.    
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TABLE 2. Summary of the effect of nutrition assessment and counseling (NAC) plus cash or food transfers on ART adherence and 
retention in care. 
 
 
 
ART=antiretroviral therapy; MPR=medication possession ratio; CI=confidence interval; LTFU=loss to follow-up 
* p<0.05 **p<0.01 
a. Unadjusted intent-to-treat estimate using Bonferroni’s adjustment for multiple comparisons.    
b. Adjusted for site and for baseline imbalances including WHO clinical stage, occupation, and language.    
c. The proportion of patients with MPR ≥95% during the 0-6 month interval.    
d. The proportion of patients with MPR ≥80% during the 0-6 month interval.    
e. The proportion of time an individual is in possession of ≥ 1 ART dose or prescription for ART.    
f. The proportion of scheduled visits completed during the 0-6 month observation period.    
g. The proportion of patients with no evidence of HIV primary care at 6 months, defined not seen for at least 90 days since the last appointment scheduled prior to 
6 months.
NAC only
NAC + 
Cash
NAC + 
Food
NAC + Cash                 
vs. NAC only
NAC + Food             
vs. NAC only
NAC + Cash         
vs. NAC + Food
NAC + Cash                 
vs. NAC only
NAC + Food               
vs. NAC only
NAC + Cash            
vs. NAC + Food
6 months
MPR≥95%c 79.5% 63.4% 85.0% 79.2% 21.6 (9.8, 33.4)** 15.8 (3.8, 27.9)** 5.7 (-1.2, 12.7) 23.5 (12.2, 34.7)** 17 (5.5, 28.5)** 6.4 (-0.1, 13.0)
MPR≥80%d 88.9% 79.5% 93.1% 87.7% 13.6 (3.9, 23.3)** 8.3 (-1.8, 18.3) 5.3 (0, 10.7)* 15.2 (6.2, 24.3)** 9.4 (0.1, 18.8)* 5.8 (0.8, 10.8)*
MPRe 92.8% 85.4% 95.1% 92.9% 9.7 (5.6, 13.8)** 7.5 (3.4, 11.6)** 2.2 (-0.7, 5.1) 10.5 (6.5, 14.4)** 8.0 (4.1, 11.9)** 2.5 (-0.3, 5.2)
12 months
MPR≥95% 67.5% 55.4% 74.9% 64.0% 19.5 (6.9, 32.1)** 8.7 (-4.2, 21.5) 10.8 (2.5, 19.2)** 20.3 (8.4, 32.2)** 9.5 (-2.6, 21.7) 10.8 (3.0, 18.6)**
MPR≥80% 85.8% 81.3% 89.3% 83.6% 8.1 (-1.6, 17.7) 2.4 (-7.7, 38.1) 5.7 (-0.5, 11.9) 8.5 (-1.0, 18.0) 2.5 (-7.3, 38.4) 5.9 (-0.1, 12.0)
MPR 90.1% 83.3% 93.0% 89.5% 9.7 (4.9, 14.5)** 6.2 (1.4, 11.0)** 3.5 (0.2, 6.8)* 10.3 (5.6, 15)** 6.6 (1.9, 11.3)** 3.7 (0.5, 7.0)*
6 months
Appointment attendance f 93.5% 82.6% 96.1% 94.5% 13.5 (9.1, 17.8)** 11.8 (7.5, 16.2)** 1.7 (-1.4, 4.7) 13.9 (9.5, 18.3)** 12.2 (7.8, 16.6)** 1.8 (-1.3, 4.8)
Lost to follow-up at 6 monthsg 2.6% 10.9% 0.9% 1.5% -10.0 (-17.3, -2.8)** -9.4 (-16.7, -2.1)** -0.7 (-2.7, 1.4) -10.3 (-17.7, -3.0)** -9.6 (-17.0, -2.1)** -0.8 (-2.8, 1.3)
12 months
Appointment attendance 92.1% 83.4% 94.7% 92.3% 11.3 (7.2, 15.5)** 8.9 (4.7, 13.1)** 2.4 (-0.5, 5.3) 11.8 (7.6, 16.0)** 9.2 (5.1, 13.4)** 2.6 (-0.4, 5.5)
Lost to follow-up at 12 months 9.5% 17.3% 6.7% 9.7% -10.6 (-20.1, -1.1)* -7.6 (-17.4, 2.1) -3.0 (-8.3, 2.3) -11.9 (-21.7, -2.0)* -8.5 (-18.6, 1.7) -3.4 (-8.7, 1.9)
Adjusted between-group differenceb  (% [95% CI])Between-group differencea  (% [95% CI])
Outcome Overall
Study group
Adherence to ART
Retention in care
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FIGURE 2. Effect of nutrition assessment and counseling (NAC) plus cash or food transfers on 
ART adherence (MPR≥95%), by quarter. 
 
 
 
MPR=medication possession ratio, NAC=nutrition assessment and counseling 
*Restricted to individuals in possession of at least one dose during the interval.      
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TABLE 3. Relative hazard of LTFU by study group and follow-up interval.a,b   
 
Study group 
0-3 months  3-6 months  6-9 months 
HRa 95% CI  HRa 95% CI  HRa 95% CI 
NAC only 1.0 ---  1.0 ---  1.0 --- 
NAC+Cash 0.07 (0.02, 0.24)**  0.56 (0.17, 1.83)  1.13 (0.24, 5.26) 
NAC+Food 0.12 (0.04, 0.35)**  0.94 (0.30, 2.89)  1.63 (0.36, 7.38) 
 
HRa=adjusted hazard ratio. CI=confidence interval. 
* p<0.05 **p<0.01 
a. Adjusted for site and for baseline imbalances including WHO clinical stage, occupation, and language. The model 
includes an interaction between study arm and categorical time at 3 and 6 months to relax the proportional hazards 
assumption. 
b. LTFU was defined as ≥3 months since the last scheduled visit. By definition, follow-up time between 9 and 12 
months could not be classified as LTFU and is therefore not included in the model.
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FIGURE 3. Kaplan-Meier curves of the percent of participants in care over time, stratified by 
study arm (nutrition assessment and counseling (NAC) plus cash or food transfers)a,b 
 
 
[SEE ATTACHED FIGURE] 
 
 
a. Log-rank test for equality of the survival functions: p<0.01 
b. The proportion of participants retained in care was defined as one minus the probability of LTFU (≥3 months 
since the last scheduled visit). By definition, follow-up time between 9 and 12 months could not be classified as 
LTFU and is therefore not included on the graph.  
 
